New York: It has been a record year for corporate deals.
Companies made more than $4.7 trillion in deals so far this year, surpassing 2007 as the top year for deals, according to Dealogic. The most recent deal, a tie-up of Dow Chemical and DuPont announced Friday, adds more than $60 billion to the total.
Here's a look back at the top deals, ranked by Dealogic.
1. Pfizer and Allergan
The deal would create the world's largest drug company, bringing Pfizer's erectile dysfunction drug Viagra and Allergan's wrinkle treatment Botox under one company.
Value: $148.6 billion
2. Anheuser-Busch InBev and SABMiller
AB InBev, already the world's largest brewer, will get even bigger after the deal closes. AB InBev makes Budweiser beer, while SABMiller makes Miller Genuine Draft.
Value: $105.6 billion
3. Royal Dutch Shell and BG Group
Oil and gas company Shell says it wants to buy rival BG Group to boost its presence in the liquefied natural gas market.
Value: $69.8 billion
4. Dell and EMC
Dell, the maker of personal computers, is buying EMC to get into the growing data-storage industry.
Value: $66 billion
5. Dow Chemical and DuPont
The two companies expect to combine and then split into three publicly traded companies focusing on agriculture, material science and specialty products.
Value: $62.4 billion
6. Charter Communications and Time Warner Cable
Combining the cable companies will create one of the largest TV and Internet providers in the U.S.
Value: $56.8 billion
7. HJ Heinz and Kraft Foods Group
HJ Heinz buying Kraft Foods created the third-largest food company, bringing together well-known brands Oscar Mayer hot dogs, Ore-Ida frozen french fries and Heinz ketchup.
Value: $53.8 billion
8. Anthem and Cigna
Based on enrollments, Anthem buying Cigna would create the nation's largest health insurer.
Value: $51.9 billion
9. PayPal split
E-commerce company eBay Inc. split off payments company PayPal into a separate, publicly traded company.
Value: $49.2 billion
10. Teva Pharmaceutical and Allergan Generics
Pharmaceutical company Teva is in the process of buying Allergan's generic drug business.
Value: $40.5 billion